Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 219

Sort by

Sort Order Select

Journal Articles

Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

Blood (2025) 146 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2025-LBA-6

Published: 2025

Journal Articles

Prognostic significance of IKZF1 deletion subtypes in ph-negative BCP-ALL: Biallelic-null deletion predicts the worst survival in TP53-wild type patients

Seung-Hwan Lee, Daehun Kwag, Gi June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Heeje Kim, Chang-Ki Min, Seok-Goo Cho, Jae-Ho Yoon

Blood (2025) 146 (Supplement 1): 5149.

https://doi.org/10.1182/blood-2025-5149

Published: 2025

Journal Articles

Visualizing systemic light chain amyloidosis with 18f-flutemetamol PET/CT: Correlation with biomarkers and clinical outcome

Sung-Soo Park, Eun Ji Han, Jung Yeon Lee, Joo Hyun O, Mi-Hyang Jung, Jong-Chan Youn, Heeje Kim, Chang-Ki Min

Blood (2025) 146 (Supplement 1): 2575.

https://doi.org/10.1182/blood-2025-2575

Published: 2025

Journal Articles

Revisiting the role of second allogeneic HCT for post-transplant relapse in acute lymphoblastic leukemia: Comparative outcomes in the era of targeted therapies

Jaehyun Ahn, Daehun Kwag, Gi June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Heeje Kim, Chang-Ki Min, Seok-Goo Cho, Jae-Ho Yoon

Blood (2025) 146 (Supplement 1): 1548.

https://doi.org/10.1182/blood-2025-1548

Published: 2025

Journal Articles

Teclistamab in a large cohort of ~100 Asian patients with triple-class exposed multiple myeloma: Experience from trials and non-trial settings

Blood (2025) 146 (Supplement 1): 5815.

https://doi.org/10.1182/blood-2025-5815

Published: 2025

Journal Articles

Earlier detection of transplant-associated thrombotic microangiopathy using harmonization criteria: A real-world comparative evaluation with conventional criteria

Seonghan Lee, Byung-Sik Cho, Ka Young Kim, So Yeon Park, Kyoung Il Min, Hohyung Nam, Daehun Kwag, Jung Yeon Lee, Seonggyu Byeon, Gi June Min, Sung-Soo Park, Silvia Park, Jae-Ho Yoon, Ki-Seong Eom, Yoo-Jin Kim, Chang-Ki Min, Seok-Goo Cho, Heeje Kim

Blood (2025) 146 (Supplement 1): 5999.

https://doi.org/10.1182/blood-2025-5999

Published: 2025

Journal Articles

Belantamab mafodotin (belamaf) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients (pts) with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM): A focus on treatment efficacy and management/resolution of ocular events in the Phase 1 dreamm-9 study

Blood (2025) 146 (Supplement 1): 5840.

https://doi.org/10.1182/blood-2025-5840

Published: 2025

Journal Articles

Phase I/II study of mezigdomide and elranatamab for relapsed/refractory multiple myeloma patients (MELT-MM): Initial results from part 1

Ja Min Byun, Chang-Ki Min, Kihyun Kim, Dok Hyun Yoon, Sung-Hoon Jung, Wee-Joo Chng, Chandramouli Nagarajan, Youngil Koh

Blood (2025) 146 (Supplement 1): 5835.

https://doi.org/10.1182/blood-2025-5835

Published: 2025

Journal Articles

Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis

Blood (2025) 146 (Supplement 1): 5820.

https://doi.org/10.1182/blood-2025-5820

Published: 2025

Journal Articles

Safety and efficacy of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma from Phase 1b of redirectt-1: Results with an extended median follow-up of 3 years

Blood (2025) 146 (Supplement 1): 701.

https://doi.org/10.1182/blood-2025-701

Published: 2025

Journal Articles

Optimal infection prophylaxis strategy for relapsed/refractory multiple myeloma patients undergoing elranatamab therapy (OPTIMUS-EL)

Ja Min Byun, Dong Hyun Kim, Youngil Koh, Chang-Ki Min, Kihyun Kim, Hee Jeong Cho, Ji Yun Lee

Blood (2025) 146 (Supplement 1): 8237.

https://doi.org/10.1182/blood-2025-8237

Published: 2025

Journal Articles

Impact of belantamab mafodotin–containing regimens on renal function in patients with Relapsed/Refractory multiple myeloma (RRMM) and mild/moderate renal impairment in the dreamm-7 and dreamm-8 trials

Blood (2025) 146 (Supplement 1): 2260.

https://doi.org/10.1182/blood-2025-2260

Published: 2025

Journal Articles

Clinical outcomes and prognostic factors in AML patients undergoing second allogeneic hematopoietic stem cell transplantation

Hohyung Nam, Byung-Sik Cho, Hyunyee Rosa Cho, Ka Young Kim, Kyoung Il Min, So Yeon Park, Daehun Kwag, Seonggyu Byeon, Gi-June Min, Jung Yeon Lee, Sung-Soo Park, Silvia Park, Jae-Ho Yoon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Chang-Ki Min, Seok-Goo Cho, Heeje Kim

Blood (2025) 146 (Supplement 1): 7707.

https://doi.org/10.1182/blood-2025-7707

Published: 2025

Journal Articles

MRD-guided outcome analysis of ponatinib plus hyper-CVAD versus historical imatinib in ph-positive ALL: Impact of early response and dose-adjusted ponatinib

Kyoung Il Min, Daehun Kwag, Gi June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Heeje Kim, Chang-Ki Min, Seok-Goo Cho, Jae-Ho Yoon

Blood (2025) 146 (Supplement 1): 3327.

https://doi.org/10.1182/blood-2025-3327

Published: 2025

Journal Articles

Impact of initial FLT3-ITD mutated clone numbers on clinical outcomes in Acute Myeloid Leukemia

Daehun Kwag, Gi June Min, Sung-Soo Park, Silvia Park, Jae-Ho Yoon, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Chang-Ki Min, Seok-Goo Cho, Heeje Kim

Blood (2025) 146 (Supplement 1): 1638.

https://doi.org/10.1182/blood-2025-1638

Published: 2025

Journal Articles

Clinical significance of apoe genotypes in older adults with Acute Myeloid Leukemia: Insights from a consecutively treated cohort

Daehun Kwag, Byung-Sik Cho, Gi June Min, Sung-Soo Park, Silvia Park, Jae-Ho Yoon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Chang-Ki Min, Seok-Goo Cho, Heeje Kim

Blood (2025) 146 (Supplement 1): 1636.

https://doi.org/10.1182/blood-2025-1636

Published: 2025

Journal Articles

Comparative efficacy of TBI-based vs. non-TBI reduced toxicity conditioning regimens in adult ALL undergoing allogeneic HCT in CR1: Improved outcomes with TBI-based RTC and ATG/ptcy combination

Kyung won Park, Jaehyun Ahn, Daehun Kwag, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Heeje Kim, Chang-Ki Min, Seok-Goo Cho, Jae-Ho Yoon

Blood (2025) 146 (Supplement 1): 4213.

https://doi.org/10.1182/blood-2025-4213

Published: 2025

Journal Articles

Evaluating the Impact of Absolute Lymphocyte Count on Outcomes in ATG Containing Haploidentical HSCT for Acute Myeloid Leukemia

Daehun Kwag, Jung Yeon Lee, Gi June Min, Sung-Soo Park, Silvia Park, Jae-Ho Yoon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Hee-Je Kim, Chang-Ki Min, Seok-Goo Cho, Byoung-Sik Cho

Blood (2024) 144 (Supplement 1): 7327.

https://doi.org/10.1182/blood-2024-212406

Published: 2024

Journal Articles

Real-World Wutcome of Defibrotide for Treatment of Adult Patients Who Developed Severe Hepatic VOD/SOS after Allogeneic Hematopoietic Cell Transplantation

Jae-Ho Yoon, Daehun Kwag, Gi June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Chang-Ki Min, Seok-Goo Cho, Seok Lee

Blood (2024) 144 (Supplement 1): 7326.

https://doi.org/10.1182/blood-2024-212062

Published: 2024

Journal Articles

Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study

Blood (2024) 144 (Supplement 1): 3369.

https://doi.org/10.1182/blood-2024-199733

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

Prognostic significance of IKZF1 deletion subtypes in ph-negative BCP-ALL: Biallelic-null deletion predicts the worst survival in TP53-wild type patients

Visualizing systemic light chain amyloidosis with 18f-flutemetamol PET/CT: Correlation with biomarkers and clinical outcome

Revisiting the role of second allogeneic HCT for post-transplant relapse in acute lymphoblastic leukemia: Comparative outcomes in the era of targeted therapies

Teclistamab in a large cohort of ~100 Asian patients with triple-class exposed multiple myeloma: Experience from trials and non-trial settings

Earlier detection of transplant-associated thrombotic microangiopathy using harmonization criteria: A real-world comparative evaluation with conventional criteria

Belantamab mafodotin (belamaf) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients (pts) with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM): A focus on treatment efficacy and management/resolution of ocular events in the Phase 1 dreamm-9 study

Phase I/II study of mezigdomide and elranatamab for relapsed/refractory multiple myeloma patients (MELT-MM): Initial results from part 1

Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis

Safety and efficacy of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma from Phase 1b of redirectt-1: Results with an extended median follow-up of 3 years

Optimal infection prophylaxis strategy for relapsed/refractory multiple myeloma patients undergoing elranatamab therapy (OPTIMUS-EL)

Impact of belantamab mafodotin–containing regimens on renal function in patients with Relapsed/Refractory multiple myeloma (RRMM) and mild/moderate renal impairment in the dreamm-7 and dreamm-8 trials

Clinical outcomes and prognostic factors in AML patients undergoing second allogeneic hematopoietic stem cell transplantation

MRD-guided outcome analysis of ponatinib plus hyper-CVAD versus historical imatinib in ph-positive ALL: Impact of early response and dose-adjusted ponatinib

Impact of initial FLT3-ITD mutated clone numbers on clinical outcomes in Acute Myeloid Leukemia

Clinical significance of apoe genotypes in older adults with Acute Myeloid Leukemia: Insights from a consecutively treated cohort

Comparative efficacy of TBI-based vs. non-TBI reduced toxicity conditioning regimens in adult ALL undergoing allogeneic HCT in CR1: Improved outcomes with TBI-based RTC and ATG/ptcy combination

Evaluating the Impact of Absolute Lymphocyte Count on Outcomes in ATG Containing Haploidentical HSCT for Acute Myeloid Leukemia

Real-World Wutcome of Defibrotide for Treatment of Adult Patients Who Developed Severe Hepatic VOD/SOS after Allogeneic Hematopoietic Cell Transplantation

Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only